309 related articles for article (PubMed ID: 23334333)
1. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
Nagano O; Okazaki S; Saya H
Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
[TBL] [Abstract][Full Text] [Related]
2. [Redox regulation in cancer stem cells].
Saya H
Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
4. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
5. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
[TBL] [Abstract][Full Text] [Related]
6. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
Yoshikawa M; Tsuchihashi K; Ishimoto T; Yae T; Motohara T; Sugihara E; Onishi N; Masuko T; Yoshizawa K; Kawashiri S; Mukai M; Asoda S; Kawana H; Nakagawa T; Saya H; Nagano O
Cancer Res; 2013 Mar; 73(6):1855-66. PubMed ID: 23319806
[TBL] [Abstract][Full Text] [Related]
7. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
[TBL] [Abstract][Full Text] [Related]
8. Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Ju HQ; Lu YX; Chen DL; Tian T; Mo HY; Wei XL; Liao JW; Wang F; Zeng ZL; Pelicano H; Aguilar M; Jia WH; Xu RH
Theranostics; 2016; 6(8):1160-75. PubMed ID: 27279909
[TBL] [Abstract][Full Text] [Related]
9. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells.
Tamada M; Nagano O; Tateyama S; Ohmura M; Yae T; Ishimoto T; Sugihara E; Onishi N; Yamamoto T; Yanagawa H; Suematsu M; Saya H
Cancer Res; 2012 Mar; 72(6):1438-48. PubMed ID: 22293754
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
11. Elevated level of mitochondrial reactive oxygen species via fatty acid β-oxidation in cancer stem cells promotes cancer metastasis by inducing epithelial-mesenchymal transition.
Wang C; Shao L; Pan C; Ye J; Ding Z; Wu J; Du Q; Ren Y; Zhu C
Stem Cell Res Ther; 2019 Jun; 10(1):175. PubMed ID: 31196164
[TBL] [Abstract][Full Text] [Related]
12. Regulation of alternative splicing of CD44 in cancer.
Prochazka L; Tesarik R; Turanek J
Cell Signal; 2014 Oct; 26(10):2234-9. PubMed ID: 25025570
[TBL] [Abstract][Full Text] [Related]
13. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.
Ishimoto T; Nagano O; Yae T; Tamada M; Motohara T; Oshima H; Oshima M; Ikeda T; Asaba R; Yagi H; Masuko T; Shimizu T; Ishikawa T; Kai K; Takahashi E; Imamura Y; Baba Y; Ohmura M; Suematsu M; Baba H; Saya H
Cancer Cell; 2011 Mar; 19(3):387-400. PubMed ID: 21397861
[TBL] [Abstract][Full Text] [Related]
14. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
16. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.
Ryoo IG; Lee SH; Kwak MK
Oxid Med Cell Longev; 2016; 2016():2428153. PubMed ID: 26682001
[TBL] [Abstract][Full Text] [Related]
17. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches.
Williams K; Motiani K; Giridhar PV; Kasper S
Exp Biol Med (Maywood); 2013 Mar; 238(3):324-38. PubMed ID: 23598979
[TBL] [Abstract][Full Text] [Related]
18. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
19. Tumor and its microenvironment: a synergistic interplay.
Catalano V; Turdo A; Di Franco S; Dieli F; Todaro M; Stassi G
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):522-32. PubMed ID: 24012661
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells.
Dando I; Cordani M; Dalla Pozza E; Biondani G; Donadelli M; Palmieri M
Oxid Med Cell Longev; 2015; 2015():425708. PubMed ID: 26064420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
